[F-18]Fluoro-DOPA PET Imaging of Brain Tumors in Children

This study has been withdrawn prior to enrollment.
(No participants ever enrolled.)
Sponsor:
Information provided by (Responsible Party):
Children's Hospital Medical Center, Cincinnati
ClinicalTrials.gov Identifier:
NCT00556153
First received: November 7, 2007
Last updated: January 7, 2013
Last verified: January 2013

November 7, 2007
January 7, 2013
February 2013
Not Provided
Increased uptake of [F-18]FDOPA in pediatric brain tumors compared to contralateral normal brain tissue as measured by standardized uptake value and tumor/non-tumor uptake ratios [ Time Frame: 15-30 minutes after IV administration ] [ Designated as safety issue: No ]
Increased uptake of [F-18]FDOPA in pediatric brain tumors compared to contralateral normal brain tissue as meased by stanfdardized uptake value and tumor/non-tumor uptake ratios [ Time Frame: 15-30 minutes after IV administration ]
Complete list of historical versions of study NCT00556153 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
[F-18]Fluoro-DOPA PET Imaging of Brain Tumors in Children
[F-18]Fluoro-DOPA PET Imaging of Brain Tumors in Children

The first phase of the study will investigate if there is increased uptake of [F-18]FDOPA in pediatric brain tumors when compared to normal brain tissue.

The first phase of the study will investigate if there is increased uptake of [F-18]FDOPA in pediatric brain tumors when compared to normal brain tissue. Tne subjects between ages 5 and 17 years will be studies, to determine if there is increased uptake of [F-18]FDOPA in pediatric brain tumors when compared to normal brain tissue. Drug safety will also be monitored.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Children ages 5-15 years, with brain tumors

Brain Tumors
Drug: [F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical
A single dosage of the diagnostic drug will be administered to individuals who meet inclusion criteria after informed consent.
Phase I
Children, ages 5-15 years with brain tumors
Intervention: Drug: [F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
February 2013
Not Provided

Inclusion Criteria:

  • Documented brain tumor at diagnosis or relapse, including high grade glioma, low grade glioma, medulloblastoma including PNET, optic pathway glioma, brainstem glioma, ependymoma.

Exclusion Criteria:

  • Pregnancy
  • Requirement for sedation
  • Lack of informed consent
Both
5 Years to 15 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00556153
CCHMC IRB# 04-09011
No
Children's Hospital Medical Center, Cincinnati
Children's Hospital Medical Center, Cincinnati
Not Provided
Principal Investigator: Michael J Gelfand, M.D. Cincinnati Children's Hospital, Cincinnati, OH
Children's Hospital Medical Center, Cincinnati
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP